1. Avery, M.E. and Mead, J., 1959, Surface properties in relation to atelectasis and hyaline membrane disease, Am. J. Dis. Child., 97: 517–523.
2. Clements, J.A., 1957, Surface tension of lung extracts, Proc. Soc. Exp. Biol. Med., 95: 170–172.
3. Guyton, A.C., Moffatt, D.S., and Adair, T.A., 1984, Role of alveolar surface tension in transepithelial movement of fluids, in: Pulmonary Surfactant”, B. Robertson, L.M.G. van Golde, and J.J. Batenburg, eds., Elsevier, Amsterdam, pp 171–185.
4. Hein, T., Lachmann, B., Armbruster, S., Smit, J.M., Voelkel, N., and Erdmann, W., 1987, Pulmonary surfactant inhibits the cardiovascular effects of platelet activating factor (PAF), 5-hydroxytryptamine (5-HT) and angiotensin II. Am. Rev. Resp. Dis., 135: A506.
5. Huber, G., Mullane, J., and LaForce, F.M., 1976, The role of alveolar lining material in antibacterial defenses of the lung. Bull. Europ. Physiopath. Resp., 12: 178–179.